We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ProBioGen Will License GlymaxX® to Thermo for Use in Developing Allergy Diagnostics
Product News

ProBioGen Will License GlymaxX® to Thermo for Use in Developing Allergy Diagnostics

ProBioGen Will License GlymaxX® to Thermo for Use in Developing Allergy Diagnostics
Product News

ProBioGen Will License GlymaxX® to Thermo for Use in Developing Allergy Diagnostics


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "ProBioGen Will License GlymaxX® to Thermo for Use in Developing Allergy Diagnostics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ProBioGen has announced that Thermo Fisher Scientific has licensed its GlymaxX® technology for use in development of allergy diagnostics.

ProBioGen’s CSO, Dr. Volker Sandig, comments: “Deviating from the typical GlymaxX® application of enhancing the cell-killing potency of CHO-derived therapeutic antibodies in cancer, GlymaxX® plays out its universal applicability in a radically different field. In this case, GlymaxX® acts to prevent the formation of cross-reactive carbohydrate determinants on recombinant proteins, expressed in insect cells, which would otherwise cause the detection of IgE antibodies of a certain kind with no clinical significance. Thus, this sophisticated technology serves to add to the specificity of the diagnostics test result.”

Dr. Jon-Sverre Schanche, VP R&D for Thermo Fisher’s ImmunoDiagnostics business explains: “Our ImmunoCAP blood tests for allergen-specific IgE antibodies aid clinicians worldwide in their diagnoses of patients with allergy-like symptoms. The GlymaxX® technology will help us in our effort to develop diagnostic tests that deliver even greater clinical precision for the benefit of doctors and allergic patients worldwide.”

ProBioGen’s CEO, Dr. Wieland Wolf, added: “We are very pleased that GlymaxX®, besides its successful therapeutic application, is now employed for diagnostics as well. This proves again the versatile and intelligent solutions GlymaxX® can provide.”

Advertisement